+18%

est. 2Y upside i

HealthcareSeries B

Rank

#1640

Sector

Virtual Primary Care / AI HealthTech

Est. Liquidity

~3Y

Data Quality

Data: Low

Curai Health offers a compelling AI-driven virtual care platform with $34.6M revenue and 75% gross margins.

Last updated: July 19, 2026

Bull (15%)+80%

If an IPO window opens and Curai achieves category leadership, exit multiple expands to 6x on $55M revenue, implying $330M exit. After 20% dilution, upside is 80%.

Base (55%)+27%

Exit multiple converges to ~4x, in line with public health-tech comps, on $55M revenue = $220M exit. After 20% dilution, upside is 26.7%.

Bear (30%)-28%

Multiple compresses to 2.5x due to competition and lack of profitability, giving $137.5M exit. After 20% dilution, upside is -28.3%.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

38%

Total funding $57M against estimated entry valuation $150M gives 38% preference overhang, meaning common stock faces significant downside risk in a lower exit.

Dilution Risk

high

With no recent funding and potential cash needs, a new round in 24 months likely dilutes existing equity by 20% or more.

Secondary Liquidity

none

No secondary market activity detected; employees likely have no early liquidity options.

Questions to Ask at the Interview

Strategic questions based on Curai's data — designed to show you've done your homework.

  • 1

    “How does Curai's AI platform improve diagnosis accuracy and differentiate from incumbents like Teladoc?”

  • 2

    “What is the company's path to profitability and how does the subscription model drive recurring revenue?”

  • 3

    “Given the 2020 Series B, what is the current cap table and how might future funding rounds affect employee equity?”

Community

Valuation Sentiment

Our model estimates +18% upside. What do you think?

Anonymous. Do not share material non-public information.


Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.